Marketwire (Wed, 6:00PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,591 people get ONXX articles and Market Currents by email alert.
Get email alerts on ONXX »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
Marketwire (May 8, 2013)
-
Marketwire (May 7, 2013)
-
-
-
Marketwire (Apr 16, 2013)
-
-
-
-
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
Onyx Pharmaceuticals: Profit Ramp AheadWilliam Meyers • Mon, Jan 7 -
-
-
-
-
3 Reasons To Buy Onyx PharmaceuticalsMarkus Aarnio • Sun, May 27, 2012
-
Onyx Pharmaceutical: Highest Returning Protected Covered CallMike Phillips • Thu, Apr 26, 2012 -
Onyx's Myeloma Drug Shifts To The Slow LaneEP Vantage • Tue, Dec 13, 2011 -
Onyx: Deal Or No Deal, Time For A PayoffProhost Biotech • Tue, Nov 29, 2011 -
Onyx Pharma's Prospects Look BrightWilliam Meyers • Thu, Aug 18, 2011
-
Higher-Than-Expected Loss at OnyxZacks Investment Research • Thu, May 5, 2011 -
Onyx Pharma's Future Getting BrighterZacks Investment Research • Fri, Mar 18, 2011
-
-
-
-
Onyx Pharmaceuticals Inc. Q2 2009 Earnings Call TranscriptTue, Aug 4, 2009
-
Onyx Pharmaceuticals Inc. Q1 2009 Earnings Call TranscriptWed, May 6, 2009
-
Onyx Pharmaceuticals, Inc., Q4 2008 Earnings Call TranscriptMon, Mar 2, 2009
-
ONYX Pharmaceuticals, Inc. Q3 2008 Earnings Call TranscriptFri, Nov 7, 2008
-
Onyx Pharmaceuticals Inc. Q2 2008 Earnings Call TranscriptTue, Aug 5, 2008
-
Onyx Pharmaceuticals Inc. Q1 2008 Earnings Call TranscriptTue, May 6, 2008
-
Onyx Pharmaceuticals Inc., Q4 2007 Earnings Call TranscriptTue, Feb 19, 2008
-
Onyx Pharmaceuticals Q3 2007 Earnings Call TranscriptTue, Nov 6, 2007
-
Marketwire (May 8, 2013)
-
Marketwire (May 7, 2013)
-
Marketwire (Apr 16, 2013)
-
Marketwire (Feb 27, 2013)
-
Marketwire (Feb 21, 2013)
-
Marketwire (Feb 5, 2013)
-
Marketwire (Jan 16, 2013)
-
Marketwire (Jan 15, 2013)
-
at CNBC.com (Jan 13, 2013)
-
at CNBC.com (Jan 7, 2013)
-
at CNBC.com (Jan 7, 2013)
-
Marketwire (Jan 2, 2013)
-
Marketwire (Dec 17, 2012)
ONXX vs. ETF Alternatives
Company Description
We are a biopharmaceutical company dedicated to developing innovative therapies that target the molecular mechanisms that cause cancer. Through our internal research programs and in conjunction with our collaborators, we are applying our expertise to develop and commercialize therapies designed... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, June 28, 2012, 3:28 AM The FDA grants priority review to a cancer drug from Onyx Pharmaceuticals (ONXX) and Bayer AG (BAYRY.PK), meaning the FDA will review the drug in six months instead of the standard ten. Regorafenib is meant to treat metastatic colorectal cancer for patients in whom the disease has worsened after standard therapy. Comment! [Healthcare]
- Thursday, June 21, 2012, 9:15 AM Market preview: Stock futures are flat to lower following slightly worse than expected jobless data, although much of Europe is higher despite more woeful PMI data. S&P Benchmark -0.05%. Onyx (ONXX) +38% after an FDA panel vote goes its way, although Celgene (CELG) is -10.8% in the wake of EU regulators asking for more info on Revlimid. Later: Existing Home Sales, Philly Fed Business Outlook Comment! [Top Stories, On the Move]
-
Thursday, June 21, 2012, 9:10 AM
Premarket gainers: ONXX +37%. SUNH +36%. EGLE +22%. CHTP +13%. RAD +6%.
Losers: KEG -14%. CELG -11%. BBBY -11%. RHT -9%. MAIN -5%. Comment! [On the Move] - Thursday, June 21, 2012, 8:48 AM Onyx Pharmaceuticals (ONXX) +38.2% premarket after yesterday's FDA panel vote in favor of the company's Kyprolis drug for multiple myeloma. The final FDA approval decision is expected July 27. Shares are upgraded to Outperform from Neutral at Baird, initiated with a Buy at Deutsche Bank, and upgraded to Buy at Brean Murray. Comment! [Healthcare, On the Move]
- Wednesday, June 20, 2012, 4:49 PM An FDA panel votes 11-0 in favor of the risk/benefit assessment for Onyx Pharmaceuticals' (ONXX) Kyprolis (carfilzomib) cancer drug for multiple myeloma. ONXX shares have been halted since ~12:30, but Ligand Pharma (LGND), which is due to receive milestone payments and royalties for the drug, rose 12.8% during regular trading and is +3.8% AH. Comment! [Healthcare, On the Move]
- Monday, June 18, 2012, 12:25 PM Onyx Pharmaceuticals (ONXX -2.5%) slips after the FDA says the toxic side effects of carfilzomib, an experimental cancer drug for multiple myeloma, may outweigh its benefits. Staff reviewers are worried about the risk of patient deaths and questioned whether the effectiveness of the drug is that great, saying in a report the drug "may not provide an advantage over available therapy." 4 Comments [Healthcare]
- Friday, June 8, 2012, 2:31 PM Onxx Pharmaceuticals (ONXX +7.6%) shares surge after BofA Merrill issues an upgrade to Buy and raises its target price to $57 from $47, citing high expectations for Kyprolis. Physician feedback has turned significantly more supportive on Kyprolis efficacy, the firm says, expecting the trend to continue as experts gain experience and publish long-term follow-up results. Comment! [Healthcare, Quick Ideas, On the Move]
- Monday, June 4, 2012, 2:03 PM Baird is defending Onyx Pharmaceuticals (ONXX -7.7%) mixed presentation yesterday at ASCO yesterday, saying that any weakness in the stock would be buying opportunity. The company presented both positive and negative data for Kyprolis, but Baird thinks it could be a best-in-class protease inhibitor that will eventually gain approval. It maintains its Neutral rating, but raises its price target to $45 from $41. Comment! [Healthcare, On the Move]
- Monday, June 4, 2012, 10:32 AM Adam Feuerstein details 12 winners and losers from the ASCO oncology conference: The winners include Bristol-Myers (BMY) for its anti-PD-1 immunotherapy, which "has blockbuster potential across several solid tumors." Onyx (ONXX) is both, as Carfilzomib is a "real multiple myeloma drug" but investors are pessimistic about its FDA chances. Comment! [Healthcare, Quick Ideas]
- Thursday, May 24, 2012, 11:24 AM Onyx Pharmaceuticals (ONXX +4.7%) says that Bayer (BAYRY.PK) has submitted a New Drug Application to the FDA seeking approval for the oral multi-kinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer. Regorafenib is a Bayer compound, and Onyx will receive a royalty on global net sales. Separately, Bernstein initiates the shares with an Outperform rating. Comment! [Healthcare, On the Move]
- Tuesday, May 22, 2012, 4:54 AM Bayer (BAYRY.PK) and Onyx Pharmaceuticals (ONXX) announce a Phase 3 trial of Nexavar tablets in patients with certain lung cancers did not meet its primary endpoint of improving overall survival. Comment! [Healthcare]
-
Thursday, May 17, 2012, 9:10 AM
Premarket gainers: VELT +11%. SHLD +10%. CTRP +9%. BYD +7%. GALE +6%. ONXX +6%. HLF +5%.
Losers: AAP -11%. DNDN -6%. Comment! [On the Move] - Wednesday, May 2, 2012, 4:19 PM ONYX Pharmaceuticals (ONXX): Q1 EPS of -$0.68 misses by $0.08. Revenue of $72.3M (+7.3% Y/Y) beats by $2.4M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, May 2, 2012, 12:10 AM Notable earnings after Wednesday's close: AGNC, ALL, APKT, ATML, AWK, CLR, CXO, CXW, DCT, EIX, ESS, EXPD, EXXI, GMCR, HIG, HTZ, IO, JDSU, KIM, LBTYA, LNC, MELI, MTD, MUR, NGD, NLY, ONNN, ONXX, PPO, PRU, PXD, RIG, SCCO, SHO, SUN, SYMC, TSO, V, WFM, WLT, YELP Comment! [Earnings]
- Tuesday, May 1, 2012, 5:35 PM Notable earnings after Wednesday's close: AGNC, ALL, APKT, ATML, AWK, CLR, CXO, CXW, DCT, EIX, ESS, EXPD, EXXI, GMCR, HIG, HTZ, IO, JDSU, KIM, LBTYA, LNC, MELI, MTD, MUR, NGD, NLY, ONNN, ONXX, PPO, PRU, PXD, RIG, SCCO, SHO, SUN, SYMC, TSO, V, WFM, WLT, YELP Comment! [Earnings]
- Friday, April 27, 2012, 9:05 AM Shares of Onyx Pharmaceuticals (ONXX) trail off 2.2% premarket on word that Warner Chilcott could be snapped up by a larger fish - possibly posing a competitive disadvantage to the biopharmaceutical firm. Comment! [On the Move, Healthcare]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Justin M. Hall
8/6/11 12A ET: (ONXX, ITMN, GSK, QGEN, GPRO) BIOTECH CORRECTION Called in June 2011 => Were You Paying Attention? http://seekingalpha.com/p/4bsg - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Barry Bazzell
(VIDEO) ONXX CEO talks about pipeline of promising new cancer drugs http://bit.ly/gFHFEA - View all 0 replies
-
- View all 0 replies
LATEST REPLIES